Interpace Biosciences (OTCMKTS:IDXG – Get Free Report) released its earnings results on Monday. The business services provider reported ($0.26) earnings per share for the quarter, Zacks reports. The company had revenue of $10.37 million during the quarter. Interpace Biosciences had a return on equity of 145.40% and a net margin of 67.64%.
Interpace Biosciences Trading Down 8.6%
Interpace Biosciences stock traded down $0.52 during midday trading on Wednesday, hitting $5.48. The stock had a trading volume of 1,600 shares, compared to its average volume of 1,755. The stock has a market cap of $30.37 million, a P/E ratio of 13.70 and a beta of 0.67. Interpace Biosciences has a 12 month low of $4.95 and a 12 month high of $7.45. The business has a fifty day moving average price of $6.40 and a 200 day moving average price of $8.05.
About Interpace Biosciences
Interpace Biosciences is a molecular diagnostics company that develops and provides tests to help clinicians assess cancer risk and guide treatment decisions. Its services combine molecular analysis with pathology and related diagnostic expertise. The company’s tests focus on conditions including pancreatic cysts and thyroid nodules. Its offerings have included PancraGEN for pancreatic cyst assessment, as well as ThyGeNEXT and ThyraMIR for evaluating thyroid nodules. Interpace has also offered molecular testing for gastrointestinal cancers.
Read More
- Five stocks we like better than Interpace Biosciences
- SpaceX’s Wild Ride Puts 2 Space Stocks and a Weekly-Payout ETF in Focus
- Palantir’s Political Controversy Is Hiding a Much Bigger Story
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
Receive News & Ratings for Interpace Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
